Navigation Links
AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Date:12/18/2009

QUEBEC CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH. Termination of the agreement will be effective January 9, 2010.

Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the prostate which, as announced by the Company last week, did not meet its primary endpoint.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "The termination of our agreement with sanofi-aventis U.S. was expected in light of last week's announcement. Our clinical development efforts will now be focused on the following late-stage compounds: in oncology, Keryx, our partner and licensee in North America, has just initiated a Phase 3 trial in multiple myeloma with perifosine, our oral PI3K/Akt inhibitor compound. We are also currently evaluating further development plans for AEZS-108, our targeted doxorubicin conjugate, after recent positive Phase 2 results in ovarian and endometrial cancer. In endocrinology, we are in the process of reactivating a Phase 3 trial with our oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on oncology and endocrine therapy, with proven expertise in drug discovery, development and commerc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
2. AEterna Zentaris Announces Appointment of New Board Member
3. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
6. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
7. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
8. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
9. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
10. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
11. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... ON, July 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... additional,restructuring plans to further reduce its cash burn ... strategic alternatives that may,include potential acquisitions and mergers. ... completed an extensive review of its VP,series of ...
... NEW BRUNSWICK, N.J., July 3 Senesco,Technologies, Inc. ... announced today,that it has contracted with Polyplus-transfection (Illkirch, ... of Senesco,s,combination therapy of siRNA against Factor 5A ... Senesco has previously reported positive preclinical in vivo ...
... 3 Antigen Discovery Inc. ("ADI",formerly ImmPORT Therapeutics ... advanced genomics and proteomics tools,announced today that the ... the,National Institute of Allergy and Infectious Diseases (NIAID) ... $3 million grant will,fund efforts to further develop ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
(Date:7/24/2014)... multi-institutional team of researchers has developed a new nanoscale ... noninvasive method for assessing the function and properties of ... better diagnosis and treatment of gut diseases. ... bowel syndrome and inflammatory bowel disease all occur in ... in patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... low levels of particulate air pollution may increase the ... suggest current exposure standards could be insufficient to protect ... public is exposed to ambient air pollution at the ... suggesting a potentially large public health impact," said Lynda ...
... People with highly developed emotional sensibilities are better at ... the Journal of Consumer Research. "Consumers who understand ... such as health decisions and product choices," explain the ... Childers (University of Kentucky). "A person can know a ...
... Medical Research, led by Jos Luis Milln, Ph.D., have ... replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal ... foundation for future clinical trials for HPP patients. ... that most commonly results from a lack of vitamin ...
Cached Biology News:Even low levels of air pollution may pose stroke risk 2Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
Request Info...
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
...
Normal human AB serum, pooled...
Biology Products: